Taken together, these data suggest that rapamycin, which is an FDA-approved oral agent with a high therapeutic index, might be most effective as a preventative strategy primarily for smokers with premalignant lesions or carcinomas in situ that bear occult K-Ras mutations. Here, KRAS is linked to in situ carcinoma.